Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma by Ayako Ura, Takuo Hayashi, Kazumasa Komura, Masaki Hosoya, Kazuya Takamochi, Eiichi Sato, Satomi Saito, Susumu Wakai, Takafumi Handa, Tsuyoshi Saito, Shunsuke Kato, Kenji Suzuki, Takashi Yao, the Tokyo Metropolitan Innovative Oncology Research Group (TMIG)

Get full text

Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer by Kohei Taniguchi, Takuo Hayashi, Tomohito Tanaka, Kazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, Kazumasa Komura, Wataru Fukuokaya, Ayako Ura, Taizo Uchimoto, Ko Nakamura, Tatsuo Fukushima, Yusuke Yano, Nobushige Takahashi, Keita Nakamori, Shoko Kinoshita, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Hirofumi Uehara, Kiyoshi Takahara, Teruo Inamoto, Yoshinobu Hirose, Takahiro Kimura, Shin Egawa, Haruhito Azuma

Get full text

The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer by Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Takai, Takeshi Tsutsumi, Kohei Taniguchi, Tomohito Tanaka, Kiyoshi Takahara, Tsuyoshi Konuma, Teruo Inamoto, Yoshinobu Hirose, Fumihito Ono, Yuichi Shiraishi, Akihide Yoshimi, Haruhito Azuma

Get full text